Zobrazeno 1 - 10
of 29
pro vyhledávání: '"A. E. Miroshnikov"'
Autor:
A. L. Khokhlov, D. Yu. Grebenkin, E. K. Faeva, V. I. Kazey, A. A. Khokhlov, A. E. Miroshnikov, O. V. Lebedeva
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 1, Pp 142-153 (2023)
Introduction. As a part of the registration of the drug product a bioequivalence study of the fixed-dose combination "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia) compared with coadministered Ezetrol® (ezetimibe) and Crestor® (ros
Externí odkaz:
https://doaj.org/article/0772376aaac44f4fa872234488c64c39
Publikováno v:
Фармакокинетика и Фармакодинамика, Vol 0, Iss 4, Pp 69-77 (2023)
Introduction. A fixed dose combination of telmisartan and hydrochlorothiazide is indicated for treatment of in the treatment of arterial hypertension. The combination of these substances causes an additive effect that helps to reduce blood pressure.
Externí odkaz:
https://doaj.org/article/3018cc3ed20447719a72eaca23864772
Publikováno v:
Фармакокинетика и Фармакодинамика, Vol 0, Iss 4, Pp 62-68 (2023)
Introduction. Telmisartan is widely used in clinical practice during hypertension treatment. It is a specific angiotensin II receptor antagonist (type AT1), effective at oral intake, A bioequivalence study of Telzap® and Mikardis® was conducted wit
Externí odkaz:
https://doaj.org/article/ff1640f633fc48e1a62395e7297568f5
Autor:
A. L. Khokhlov, D. Yu. Grebenkin, E. K. Faeva, V. I. Kazey, A. A. Khokhlov, A. E. Miroshnikov, O. V. Lebedeva
Publikováno v:
Фармакокинетика и Фармакодинамика, Vol 0, Iss 1, Pp 61-74 (2022)
Introduction. The advantages of fixed-dose combination losartan + amlodipine + rosuvastatin compared to mono-drugs and two-component combinations are to increase the therapeutic efficacy, to reduce the cost of the product and to make the drug easier
Externí odkaz:
https://doaj.org/article/0c36285512054bd1a052f528905cda52
Autor:
V. Kubesh, A. L. Khokhlov, A. M. Shitova, Yu. A. Dzhurko, V. I. Kazey, A. A. Khokhlov, A. E. Miroshnikov, O. V. Lebedeva, I. K. Klaus, A. V. Zyatenkov
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 9, Iss 4, Pp 155-163 (2020)
Introduction. A fixed dose combination of telmisartan and amlodipine is widely used in clinical practice during hypertension treatment. Combination of telmisartan and amlodipine demonstrates potentiating synergistic effect on blood pressure decrease.
Externí odkaz:
https://doaj.org/article/8bfbbc454e4d40dba257927d6c21b606
Autor:
N. O. Pozdnyakov, I. N. Kagarmanyan, A. E. Miroshnikov, E. S. Emelyanov, A. A. Gruzdeva, A. M. Sirotkina, I. A. Dukhanina, A. A. Milkina, A. A. Khokhlov, S. O. Pozdnyakov
Publikováno v:
Acta Biomedica Scientifica, Vol 5, Iss 3, Pp 13-23 (2020)
In this article, we analyze the role of different variants of the KCNJ11, TCF7L2, SLC22A1, SLC22A3, CYP2C9, CYP2C8, PPARγ genes polymorphisms in efficacy of diabetes mellitus pharmacotherapy. T allele of the KCNJ11 rs2285676 gene polymorphism and G
Externí odkaz:
https://doaj.org/article/90bffad3c345457fba2a041e4979c0cf
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 8, Iss 3, Pp 101-106 (2019)
Introduction. Telmisartan is a modern antihypertensive drug, from the group of angiotensin II receptor antagonists, which, recently, has been the purpose of the development and registration of generic drug. The pharmaceutical development of telmisart
Externí odkaz:
https://doaj.org/article/79dbe4df1f844514bed1dbbed9e3d0c0
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 8, Iss 4, Pp 231-237 (2018)
Nowadays retrospective analysis of bioequivalence studies of medicinal products that have the same International Nonproprietary Name is becoming particularly relevant. Over the past years we have accumulated a sufficient pool of data in the Russian F
Externí odkaz:
https://doaj.org/article/422742a2f8974e2084f06e19f2a431d6
Publikováno v:
Acta Biomedica Scientifica, Vol 3, Iss 5, Pp 94-105 (2018)
Background. Evidence of the effect of sex on the pharmacokinetics of drugs and, accordingly, on the clinical response is significantly accumulated, because of a growing number of clinical studies of the early development of original drugs, which incl
Externí odkaz:
https://doaj.org/article/713248eeafce4665b7609405fe548eea
Autor:
A. L. Khokhlov, A. N. Yavorsky, N. O. Pozdnyakov, J. V. Rybachkova, E. S. Emelianov, A. A. Khokhlov, A. E. Miroshnikov, S. O. Pozdnyakov
Publikováno v:
Архивъ внутренней медицины, Vol 8, Iss 1, Pp 45-52 (2018)
The complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment. The aim of our work was to study the pharmacogenetics features of pharmac
Externí odkaz:
https://doaj.org/article/31bf942db4b14a65a049a70b29d53deb